Literature DB >> 12908946

Foxy, a designer tryptamine hallucinogen.

Robert Meatherall1, Pankaj Sharma.   

Abstract

Foxy is slang for 5-methoxy-N,N-diisopropyltryptamine. It has hallucinogenic properties, similar to other tryptamine compounds, and is mildly euphoric. This case report describes a 21-year-old Caucasian man who ingested a pill called Foxy containing an unknown amount of drug. He was observed in hospital for 2 h, during which time he had mild hallucinations and could not move his limbs. A urine sample was collected approximately 4 h after drug ingestion. The patient was then discharged with no follow up assessment. The 5-methoxy-N,N-diisopropyltryptamine was identified in the urine by gas chromatography-mass spectrometry. Standards prepared from the pure material were used in the identification. Quantitative analysis using the same analytical technique resulted in a urinary concentration of 1.7 micro g/mL. Through oxidative deamination, the metabolite, 5-methoxy-indole acetic acid, was formed. It was identified in the urine, and the concentration was determined to be 1.3 micro g/mL using gas chromatography-mass spectrometry. Two other compounds were discovered in the urine sample as a result of a routine drug screen. From their mass spectra, they were tentatively identified as 5-methoxy-N-isopropyltryptamine and 5-methoxy-N,N-diisopropyltryptamine-N'-oxide.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12908946     DOI: 10.1093/jat/27.5.313

Source DB:  PubMed          Journal:  J Anal Toxicol        ISSN: 0146-4760            Impact factor:   3.367


  8 in total

1.  Alterations in body temperature, corticosterone, and behavior following the administration of 5-methoxy-diisopropyltryptamine ('foxy') to adult rats: a new drug of abuse.

Authors:  Michael T Williams; Nicole R Herring; Tori L Schaefer; Matthew R Skelton; Nicholas G Campbell; Jack W Lipton; Anne E McCrea; Charles V Vorhees
Journal:  Neuropsychopharmacology       Date:  2006-10-18       Impact factor: 7.853

Review 2.  Indolealkylamines: biotransformations and potential drug-drug interactions.

Authors:  Ai-Ming Yu
Journal:  AAPS J       Date:  2008-05-03       Impact factor: 4.009

3.  Glucose and corticosterone changes in developing and adult rats following exposure to (+/-)-3,4-methylendioxymethamphetamine or 5-methoxydiisopropyltryptamine.

Authors:  Devon L Graham; Nicole R Herring; Tori L Schaefer; Charles V Vorhees; Michael T Williams
Journal:  Neurotoxicol Teratol       Date:  2009-09-06       Impact factor: 3.763

Review 4.  Recreational use, analysis and toxicity of tryptamines.

Authors:  Roberta Tittarelli; Giulio Mannocchi; Flaminia Pantano; Francesco Saverio Romolo
Journal:  Curr Neuropharmacol       Date:  2015-01       Impact factor: 7.363

Review 5.  Toxicology and Analysis of Psychoactive Tryptamines.

Authors:  Sara Malaca; Alfredo Fabrizio Lo Faro; Alice Tamborra; Simona Pichini; Francesco Paolo Busardò; Marilyn A Huestis
Journal:  Int J Mol Sci       Date:  2020-12-04       Impact factor: 5.923

6.  Prolonged delusional state triggered by repeated ingestion of aromatic liquid in a past 5-methoxy-N, N-diisopropyltryptamine abuser.

Authors:  Yasuko Fuse-Nagase; Toru Nishikawa
Journal:  Addict Sci Clin Pract       Date:  2013-04-11

Review 7.  Designer drugs: mechanism of action and adverse effects.

Authors:  Dino Luethi; Matthias E Liechti
Journal:  Arch Toxicol       Date:  2020-04-06       Impact factor: 5.153

Review 8.  Adolescent brain cognitive development (ABCD) study: Overview of substance use assessment methods.

Authors:  Krista M Lisdahl; Kenneth J Sher; Kevin P Conway; Raul Gonzalez; Sarah W Feldstein Ewing; Sara Jo Nixon; Susan Tapert; Hauke Bartsch; Rita Z Goldstein; Mary Heitzeg
Journal:  Dev Cogn Neurosci       Date:  2018-02-21       Impact factor: 5.811

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.